Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$8.03 USD
-0.34 (-4.06%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $8.04 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Ocular Therapeutix, Inc. [OCUL]
Reports for Purchase
Showing records 81 - 89 ( 89 total )
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Dextenza NDA Resubmitted on Time; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Dextenza NDA Resubmission Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2018 1Q Results Reported; Dextenza NDA Resubmission This Quarter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2017 Results Reported; Dextenza NDA Resubmission on Track in 1H18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Our Impressions of the American Academy of Ophthalmology (AAO) 2017 Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
3Q17 Results Reported; Dextenza NDA Resubmission in 1H 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2Q17 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
New CEO Commenced Employment; Restructuring Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
A Sustained Delivery Platform for Your Eyes; Initiating Coverage at Buy and $10 Price Target
Provider: H.C. Wainwright & Co., Inc.